In a new study, Researchers from institutions such as the University of Washington studied human monoclonal antibodies isolated from survivors of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS)Read More…
Kyowa Hakko Kirin announced submission of Crysvita (burosumab, KRN23) to the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of FGF-23-related hypophosphatemic rickets and osteomalacia. The active ingredient ofRead More…
Currently, the Scripps Research Institute has developed a new candidate AIDS vaccine that can effectively overcome the technical barriers of previous AIDS vaccines and stimulate powerful anti-HIV antibody responses in animal experiments.Read More…
HIV evades the body’s immune defenses through multiple mutations, and the antibodies against HIV produced by the host’s immune system follow a complex and difficult-to-track evolutionary pathway. This complexity makes it difficultRead More…
As life lies in movement, immunity relies on balance. A healthy individual has immune cells that can easily eradicate the recurring diseased cells in the body, including those potentially evolving to cancerousRead More…
Kyowa Hakko Kirin, a Japanese pharmaceutical company, recently announced that the European Commission (EC) has approved Poteligeo (mogamulizumab) to treat adult patients with relapsed or refractory mycosis fugoides (MF) or Sezary syndromeRead More…
In the past decade, tumor immunotherapy has overturned the traditional concept of treatment, especially the discovery and application of immune checkpoint molecules. The immune checkpoint can be irritating or inhibitory, and theRead More…